Chemical Modification Or The Reaction Product Thereof, E.g., Covalent Attachment Or Coupling, Etc. Patents (Class 530/402)
  • Patent number: 10703778
    Abstract: Provided is a cyclic peptide, which is represented by Formula (I) or Formula (I?) and has excellent antibody binding properties and improved chemical resistance, an affinity chromatography support, a labeled antibody, an antibody drug conjugate, and a pharmaceutical preparation. RN-Xg-[Xi-Xa-Xm-X1-X2-X3-Xn-Xb-Xj]k-Xh-RC??(I) In Formula (I), Xa and Xb each independently represent an amino acid residue derived from an amino acid, other than L-cysteine and D-cysteine, having a thiol group on a side chain and are bonded to each other through a disulfide bond, or, one of Xa and Xb represents an amino acid residue derived from an amino acid, other than L-cysteine and D-cysteine, having a thiol group on a side chain and the other represents an amino acid residue derived from an amino acid having a haloacetyl group on a side chain, and Xa and Xb are bonded to each other through a thioether bond.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: July 7, 2020
    Assignee: FUJIFILM Corporation
    Inventor: Koichi Minami
  • Patent number: 10662224
    Abstract: Provided is a cyclic peptide, which is represented by Formula (I) or Formula (I?) and has excellent antibody binding properties and improved chemical resistance, an affinity chromatography support, a labeled antibody, an antibody drug conjugate, and a pharmaceutical preparation. RN-Xg-[Xi-Xa-Xm-X1-X2-X3-Xn-Xb-Xj]k-Xh-RC??(I) In Formula (I), Xa and Xb each independently represent an amino acid residue derived from an amino acid, other than L-cysteine and D-cysteine, having a thiol group on a side chain and are bonded to each other through a disulfide bond, or, one of Xa and Xb represents an amino acid residue derived from an amino acid, other than L-cysteine and D-cysteine, having a thiol group on a side chain and the other represents an amino acid residue derived from an amino acid having a haloacetyl group on a side chain, and Xa and Xb are bonded to each other through a thioether bond.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: May 26, 2020
    Assignee: FUJIFILM Corporation
    Inventor: Koichi Minami
  • Patent number: 10541427
    Abstract: The present specification relates to a carrier-nanoparticle complex, a catalyst including the same, an electrochemical battery or a fuel cell including the catalyst, and a method for preparing the same.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: January 21, 2020
    Assignee: LG CHEM, LTD.
    Inventors: Jun Yeon Cho, Kwanghyun Kim, Sang Hoon Kim, Ran Choi, Gyo Hyun Hwang, Wonkyun Lee
  • Patent number: 10383831
    Abstract: Compounds according to Formula I are provided: and salts thereof, wherein R1, R2, R3, R4, R5, R6, R13, A, X and Y are as defined herein. Methods for preparing compounds of Formula I are also provided, as well as methods of treating cellular proliferative disorders, such as cancer, using compounds of Formula I.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: August 20, 2019
    Assignee: Temple University—Of The Commonwealth System Of Higher Education
    Inventors: M. V. Ramana Reddy, E. Premkumar Reddy
  • Patent number: 10345726
    Abstract: There is provided a method of manufacturing a toner including a toner particle containing a binder resin, the method including: process 1: preparing a mixed solution including the following components i) to iii) in an aqueous medium: i) a particular silicon compound, ii) a fine particle having a number average particle diameter of 3 nm or more and 500 nm or less, and iii) a toner base particle containing the binder resin; and process 2: adjusting a pH of the mixed solution to 7.0 or more and 12.0 or less to condense the silicon compound, wherein the fine particle has an absolute value of zeta potential of 10.0 mV or more at the pH of the mixed solution of process 1.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: July 9, 2019
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Kunihiko Nakamura, Kenta Kamikura, Maho Tanaka, Fumiya Hatakeyama
  • Patent number: 10259838
    Abstract: Described herein are methods, compositions and kits utilizing heterogeneous metal catalysts for the preparation of cycloaddition compounds, such as triazoles and biomolecules.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: April 16, 2019
    Assignee: OCCIDENTAL COLLEGE
    Inventors: Michael Hill, Andrew Udit
  • Patent number: 10030051
    Abstract: The present invention provides antibodies containing one or more modular recognition domains (MRDs) for targeting the antibodies to specific sites. The use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also provided in the invention.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: July 24, 2018
    Assignee: The Scripps Research Institute
    Inventor: Carlos F. Barbas, III
  • Patent number: 10016411
    Abstract: Conjugates of SN-38 that provide optimal drug release rates and minimize the formation of the corresponding glucuronate are described. The conjugates release SN-38 from a polyethylene glycol through a ?-elimination mechanism.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: July 10, 2018
    Assignee: ProLynx LLC
    Inventors: Gary W. Ashley, Eric L. Schneider
  • Patent number: 9714942
    Abstract: It is intended to provide a detection method and a determination method for detection target capable of detecting and determining a detection target promptly and simply with high accuracy at low cost. The detection method includes the steps of: mixing a first conjugate 10 in which a first substance containing a stimulus-responsive polymer 11 and a particulate magnetic substance 19 is conjugated to a first antibody 13 against a detection target 50 with a sample; applying a magnetic force after placing the resulting mixture in a condition capable of aggregating the stimulus-responsive polymer 11; measuring a generated magnetic field; and detecting the detection target 50 based on the degree of increase in the magnetic field after applying the magnetic force.
    Type: Grant
    Filed: December 25, 2008
    Date of Patent: July 25, 2017
    Assignees: JNC CORPORATION, ORTHO-CLINICAL DIAGNOSTICS KABUSHIKI KAISHA
    Inventors: Toshiya Sawai, Eri Oowada, Hirokazu Nagaoka, Satoru Sugita, Toshiya Ueki
  • Patent number: 9637639
    Abstract: The present invention relates to a method of producing a dispersion comprising a) mixing an aqueous dispersion of silanized colloidal silica particles with at least one organic compound containing at least two hydroxyl groups to provide an aqueous dispersion of silanized colloidal silica particles and said at least one organic compound, wherein the mixing is performed in the substantial absence of any monofunctional alcohol b) withdrawing water from the formed aqueous dispersion until the remainder of water in the dispersion is below about 10 wt %. The invention also relates to a dispersion obtainable therefrom and the use of the dispersion.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: May 2, 2017
    Assignee: AKZO NOBEL CHEMICALS INTERNATIONAL B.V.
    Inventors: Peter Harry Johan Greenwood, Hans Lagnemo
  • Patent number: 9636393
    Abstract: International patent application WO99/61053 discloses immunogenic compositions that comprise N. meningitidis serogroup C oligosaccharide conjugated to a carrier, in combination with N. meningitidis serogroup B outer membrane protein. These are disclosed in the present application in combination with further Neisserial proteins and/or protective antigens against other pathogenic organisms (e.g. Haemophilus influenzae, DTP, HBV, etc.).
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: May 2, 2017
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Marzia Monica Giuliani, Mariagrazia Pizza, Rino Rappuoli
  • Patent number: 9610356
    Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition to a subject in need thereof, which composition contains a lipocalin mutein or a fragment or a variant thereof capable of increasing the bioavailability of iron in the subject.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: April 4, 2017
    Assignee: Pieris Pharmaceutical GmbH
    Inventors: Andreas Hohlbaum, Hendrik Gille, Stefan Trentmann, Laurent Audoly, Andrea Allensdorfer
  • Patent number: 9506056
    Abstract: Materials and methods for modulating cellular uptake of functionalized nanoparticles are provided. Also provided are materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: November 29, 2016
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, David A. Giljohann, Dwight Seferos
  • Patent number: 9341633
    Abstract: There are provided a pre-treatment technique for a glycated hemoglobin-containing sample, which is a simple and convenient treatment, is free from problems in storage stability and environmental aspects, and is capable of exposing an epitope sufficiently in a short time; and an method for an immunological assay of glycated hemoglobin using this technique. A method for pre-treating a glycated hemoglobin-containing sample for an immunological assay of glycated hemoglobin, the method includes treating a glycated hemoglobin-containing sample with a pre-treatment solution containing (A) guanidine or a salt thereof and (B) a nonionic surfactant and/or a nitrite.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: May 17, 2016
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Osamu Miyazaki, Syunsuke Kurashita, Kohei Takubo
  • Patent number: 9303064
    Abstract: A peptide inhibiting a matrix metalloproteinase activity, thereby improving the condition of skin and a composition containing the peptide is described, where the peptide comprises an amino acid sequence represented by the formula: Xaa1-Xaa2-Pro-Cys-Xaa3-Xaa4-Xaa5-Ser-Xaa6and has excellent bioactivities of inhibiting the activity of hyaluronic acid degrading enzymes, adipogenesis in fat cells, angiogenesis, and the like, thereby being useful for the treatment of various disease such as obesity, cancer, and inflammation.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: April 5, 2016
    Assignee: CAREGEN CO., LTD.
    Inventors: Young Ji Chung, Eun Mi Kim
  • Patent number: 9220816
    Abstract: It is provided a method of treating a disorder, the method comprising implanting in a patient an implantable device including a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: December 29, 2015
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventor: Stephen D. Pacetti
  • Patent number: 9220815
    Abstract: It is provided a polymer blend that contains a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: December 29, 2015
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventor: Stephen D. Pacetti
  • Patent number: 9198952
    Abstract: Provided herein are ligand dimers, compositions thereof, as well as methods of their use. The ligand dimers provided can comprise at least one ligand to a Her receptor and can be used to force dimerization of specific receptor pairs. The forced dimerization of specific receptor pairs can be used to control (e.g., promote or inhibit) signaling, and, therefore, the ligand dimers provided can also be used in various forms of treatment in which such signaling control is beneficial to a subject. It follows that methods for controlling signaling are provided as are various methods of treatment.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: December 1, 2015
    Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute of Technology
    Inventors: Luis M. Alvarez, Linda G. Griffith, Richard T. Lee
  • Patent number: 9107872
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: August 18, 2015
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • Patent number: 9051388
    Abstract: Chimeric ErbB ligand binding molecules having detectable binding activity for more ErbB ligands than any one of native ErbB 1, ErbB3 or ErbB4 are disclosed. Preferably, the binding molecules bind a broad spectrum and, more preferably, the full spectrum of ErbB ligands. The chimeric ErbB ligand binding molecules generally have a subunit LI derived from one of ErbB1, 3, or 4 and a subunit LII derived from another distinct ErbB receptor type. The sub-domain, SI, which joins LI and LII can be from either one of the receptor types or can have portions from both. Pharmaceutical compositions that contain the molecules and methods for the treatment of ErbB sensitive diseases are also disclosed.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: June 9, 2015
    Assignee: LIGACEPT LLC
    Inventor: Jason Hill
  • Patent number: 9040020
    Abstract: The present invention relates to novel muteins derived from human lipocalin 2 (hNGAL) and related proteins that bind a given non-natural ligand with detectable affinity. The invention also related to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. Furthermore, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: May 26, 2015
    Assignee: Technische Universitaet Muenchen
    Inventors: Arne Skerra, Andreas Eichinger, Hyun-Jin Kim
  • Patent number: 9040478
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: May 26, 2015
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
  • Patent number: 9040251
    Abstract: This invention provides a biomolecule modifying substrate comprising biomolecules selectively fixed to given regions thereon. The biomolecule modifying substrate comprises: a substrate at least comprising a first surface and a second surface; a first linker molecule comprising a hydrocarbon chain and a functional group capable of selectively binding to the first surface at one end of the hydrocarbon chain, which is bound to the first surface via such functional group; a second linker molecule comprising a reactive group capable of binding to the hydrocarbon chain of the first linker molecule, which is bound to the first linker molecule via a bond between the reactive group and the hydrocarbon chain; and a biomolecule bound thereto via the second linker molecule.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: May 26, 2015
    Assignee: HITACHI HIGH-TECHNOLOGIES CORPORATION
    Inventors: Yasuhiko Tada, Hiroshi Yoshida, Toshiro Saito, Masatoshi Narahara, Hiroaki Nakagawa
  • Patent number: 9034661
    Abstract: There is disclosed a method for producing a molecule immobilizing substrate, comprising at least the steps of: forming, on a substrate, a monomolecular film including hydroxyl groups, cyano groups, or oxiranyl groups, which are oriented toward an outmost surface of the monomolecular film; and chemically modifying the hydroxyl groups, cyano groups, or oxiranyl groups of the monomolecular film to transform them into carboxyl groups, to thereby form, on the substrate, the monomolecular film including the carboxyl groups, which are oriented toward an outmost surface of the monomolecular film. There can be provided: a method for producing a molecule immobilizing substrate which is free of occurrence of an immobilized-molecule peeling problem in the case of conducting an assay by immobilizing molecules on the substrate.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: May 19, 2015
    Assignee: SHIN-ETSU CHEMICAL CO., LTD.
    Inventors: Wataru Kusaki, Toshinobu Ishihara, Takeshi Kinsho, Takeru Watanabe
  • Patent number: 9029323
    Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: May 12, 2015
    Assignee: Evotec International GmbH
    Inventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
  • Patent number: 9029328
    Abstract: The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: May 12, 2015
    Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute of Technology
    Inventors: Steven M. Jay, Linda G. Griffith, Richard T. Lee
  • Patent number: 9029516
    Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: May 12, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
  • Patent number: 9017655
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: April 28, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stuart Emanuel, Linda Engle, Ray Camphausen, Martin C. Wright, Ginger Chao Rakestraw, Marco Gottardis, Joan Carboni
  • Patent number: 9018360
    Abstract: The present invention provides a modified biotin-binding protein comprising an amino acid sequence represented by SEQ ID NO: 2 or its modified sequence and having a biotin-binding activity and replacement selected from the group consisting of: 1) replacement of the 36th serine residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 2) replacement of the 80th tryptophan residue of SEQ ID NO: 2 with a hydrophilic amino acid residue; 3) replacement of the 116th aspartic acid residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 4) replacement of the 46th proline residue of SEQ ID NO: 2 with a threonine, serine, or tyrosine residue and replacement of the 78th threonine residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 5) replacement of the 46th proline residue of SEQ ID NO: 2 with a threonine, serine, or tyrosine residue and replacement of the 116th aspartic acid residue of SEQ ID NO: 2 with an amino acid that
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: April 28, 2015
    Assignee: Japan Tobacco Inc.
    Inventors: Yoshimitsu Takakura, Masako Tsunashima, Kozue Sofuku
  • Publication number: 20150104804
    Abstract: A method for manufacturing cubic diamond nanocrystals (10) comprising the following successive steps: (a) providing crystalline diamond powder where the maximum particle size of the powder is equal or more than 2 ?m and equal or less than 1 mm; (b) milling said crystalline micron diamond powder using nitrogen jet milling micronization so as to manufacture a fine powder; (c) nanomilling the fine powder of step b) using a planetary tungsten carbide ball mill; (d) acid treating the nanomilled powder of step c); (e) extracting the cubic diamond nanocrystals (10) by centrifugation. Advantageously round-shaped cubic diamond nanocrystals are manufactured.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 16, 2015
    Inventors: Patrick Curmi, Jean-Paul Boudou, Alain Thorel, Fedor Jelezko, Mohamed Sennour
  • Patent number: 9006182
    Abstract: A light activated collagen-flavin composite layer incorporating riboflavin is applied as treatment for infected lesions. These composites have also been found to be strong tissue adheives that are effective in closing and sealing wounds, fixation of grafts/ implants and anastomoses. Advantages include speed of closure, reduced infection due to the elimination of foreign matter, evidence of accelerated wound healing and the ease of use in complex surgery, especially when watertight seals, limited access or small repair size are important factors. The riboflavin in the collagen layer is exposed to light (e.g., light having a wavelength between 360-375 nm or 440-480 nm), decomposing the riboflavin to form reactive oxygen species (ROS). Strong crosslinks between the collagen composite and tissue results. In addition, similar exposures eradicate pathogens in the wound.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: April 14, 2015
    Assignee: Conversion Energy Enterprises, Inc.
    Inventors: Barbara A. Soltz, Robert Soltz
  • Patent number: 9005600
    Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: April 14, 2015
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
  • Publication number: 20150099707
    Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Ira H. Pastan, Ronit Mazor, Masanori Onda, Byungkook Lee, Gerhard Niederfellner, Sabine Imhof-Jung, Ulrich Brinkmann, Werner Scheuer, Guy Georges
  • Patent number: 8999661
    Abstract: The invention provides compounds and methods of their use in the detection of apoptosis and necrosis both in vitro and in vivo. Also provided are compounds and methods of their use in selective delivery of agents to cells undergoing apoptosis or necrosis. The compounds and methods are based on conjugates formed with a dehydrogenase such as lactate dehydrogenase, alcohol dehydrogenase, aldehyde dehydrogenase, and malate dehydrogenase. The compounds and methods are useful in the diagnosis and treatment of conditions characterized by apoptosis, including cancer, cardiac disease, neurologic disease including stroke, and autoimmunity. The compounds and methods offer distinct advantages over corresponding compounds and methods based on Annexin V. Also provided are methods for screening for compounds that modulate, i.e., inhibit or promote, apoptosis.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: April 7, 2015
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Andrew Kung, Pallab Banerjee
  • Publication number: 20150086482
    Abstract: The present application discloses compositions and methods of use of peptide targetable constructs for detection, diagnosis and/or imaging of cancer. In preferred embodiments, the targetable construct comprises at least one hapten, at least one fluorescent probe, a chelating moiety and a group IIIA metal-18F complex attached to the chelating moiety. For in vivo use, the labeled targetable construct is used in conjunction with a bispecific antibody comprising at least one binding site for the hapten and at least one binding site for a tumor-associated antigen. Cancers may be detected, diagnosed and/or imaged by fluorescence spectroscopy and/or PET or SPECT. Preferably, imaging is performed in intraoperative, intraperitoneal, laparoscopic, endoscopic or intravascular procedures.
    Type: Application
    Filed: December 9, 2014
    Publication date: March 26, 2015
    Inventors: Celeste Aida S. Regino, William J. McBride, Chien-Hsing Chang, David M. Goldenberg
  • Patent number: 8980276
    Abstract: The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): wherein m, n, W, -(spacer)-, X* and Y are as defined in the description. In certain embodiments, said nicotine-derived hapten-carrier conjugates can be used to prepare vaccines for the treatment and/or prevention of nicotine addiction.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: March 17, 2015
    Assignee: Pfizer Inc
    Inventors: Alan Daniel Brown, Heather Lynn Davis, David P. Gervais, Lyn Howard Jones, James R. Merson, David Cameron Pryde, David R. Stead, Michael J. McCluskie, Jennifer Marie Thorn, Paul Robert Mehelic, Parag Ashok Kolhe, Keshab Bhattacharya, Jari Ilmari Finneman, Erin Kristen Parsons, Nickolas Anastasiou
  • Publication number: 20150072398
    Abstract: The invention features compositions and methods for site-specific modification of proteins by incorporation of an aldehyde tag. Enzymatic modification at a sulfatase motif of the aldehyde tag through action of a formylglycine generating enzyme (FGE) generates a formylglycine (FGly) residue. The aldehyde moiety of FGly residue can be exploited as a chemical handle for site-specific attachment of a moiety of interest to a polypeptide.
    Type: Application
    Filed: August 20, 2014
    Publication date: March 12, 2015
    Inventors: Isaac S. Carrico, Brian L. Carlson, Peng Wu, Carolyn Bertozzi
  • Publication number: 20150071914
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Application
    Filed: May 29, 2014
    Publication date: March 12, 2015
    Applicant: Bristol-Myers Squibb Company
    Inventors: Robert James PEACH, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
  • Patent number: 8969532
    Abstract: The present invention provides processes for the manufacturing of polypeptide conjugates. In particular, the invention provides methods for the purification of polypeptide conjugates, which include at least one polymeric modifying groups, such as a poly(alkylene oxide) moiety. Exemplary poly(alkylene oxide) moieties include poly(ethylene glycol) (PEG) and poly(propylene glycol). In an exemplary process, hydrophobic interaction chromatography (HIC) is used to resolve different glycoforms of glycoPEGylated polypeptides.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: March 3, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Kyle Kinealy
  • Publication number: 20150057433
    Abstract: Reagents are disclosed for chemoselective tagging of methionine residues in peptides and polypeptides, subsequent bioorthogonal tag functionalization, and cleavage of the tags when desired to regenerate unmodified samples. This method compliments other peptide tagging strategies and adds capability for tag removal, which may be useful for release of therapeutic peptides from a carrier, or release of tagged protein digests from solid supports.
    Type: Application
    Filed: March 26, 2013
    Publication date: February 26, 2015
    Applicant: The Regents of the University of California
    Inventors: Timothy J. Deming, Jessica R. Kramer
  • Patent number: 8962804
    Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: February 24, 2015
    Assignee: City of Hope
    Inventors: John C. Williams, David A. Horne, Yuelong Ma, Heng Wei Chang, Joshua Michael Donaldson, Cindy Zer, Krzysztof Bzymek, Kendra Nicole Avery, Jun Xie
  • Patent number: 8962555
    Abstract: The present invention relates to a new homodimeric form of recombinant PlGF-1, to a process for its preparation and to compositions containing it.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: February 24, 2015
    Assignees: Dompe S.p.A., Geymonat S.p.A.
    Inventors: Gaetano D'Anniballe, Franck Martin, Giuseppe Salvia
  • Patent number: 8957189
    Abstract: The present invention, in some embodiments thereof, relates to material science in general, and, more particularly, to sequence variants of Stable Protein 1 (SP1), to uses thereof, for binding of carbon nanotubes, production of composite polymers and polymer materials, such as fabrics, based on SP1-polypeptide-carbon nanotube-complexes, and the use thereof for enhancing conductivity in tire.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: February 17, 2015
    Assignee: Fulcrum S.P. Materials Ltd.
    Inventors: Amnon Wolf, Nimrod Litvak, Elena Grimberg, Galit Cohen, Arnon Heyman, Izhar Medalsy, Danny Porath, Oded Shoseyov, Asa Eitan
  • Publication number: 20150044162
    Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with the amino acid hTRAIL281; and domain (b) which is a sequence of an effector peptide inhibiting protein synthesis, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.
    Type: Application
    Filed: November 28, 2012
    Publication date: February 12, 2015
    Inventors: Jerzy Szczepan Pieczykolan, Sebastian Pawlak, Michal Szymanik, Anna Maria Pieczykolan, Bartlomiej Maciej Zerek, Piotr Rózga, Albert Robert Jaworski, Malgorzata Izabela Teska-Kaminska
  • Publication number: 20150045664
    Abstract: The present Invention relates to the monitoring of biological substances, such as non-invasive monitoring of such substances in animal, for examples biomarkers and metabolites. Specifically, the invention further relates to such monitoring using rare earth tagged marker compounds. The invention further relates to such monitoring using laser spectroscopy or Raman spectroscopy. The invention further relates to the use of such monitoring in disease states, such as stroke, neurological disorders and cardiovascular disorders.
    Type: Application
    Filed: March 7, 2013
    Publication date: February 12, 2015
    Inventors: Sikha Saha, Gin Jose, Animesh Jha
  • Publication number: 20150045299
    Abstract: Certain embodiments are directed to novel heterotrimeric fusions in which the ectodomain of the TGF-? type II receptor (T?P?II) is coupled to the N- and C-terminal ends of the endoglin-domain of the TGF-? type III receptor (TpRIIIE). Certain embodiments are directed to novel heterotrimeric polypeptides in which the ectodomain of the TGF-? type II receptor (TI3RII) is coupled to the N- and C-terminal ends of the endoglin-domain (E domain) of the TGF-? type III receptor (TI3RIII). This trimeric receptor, known as RER, can bind all three TGF-? isoforms with sub-nanomolar affinity and is effective at neutralizing signaling induced by all three TGF-? isoforms, but not other ligands of the TGF-? superfamily, such as activins, growth and differentiation factors (GDFs), and bone morphonogenetic proteins (BMPs).
    Type: Application
    Filed: March 28, 2013
    Publication date: February 12, 2015
    Inventors: Hinck Andrew, Luzhen Sun, Christian Zwieb
  • Publication number: 20150044692
    Abstract: Identification and use of proteins fluorescently labeled and that undergo a change in fluorescence index upon binding bilirubin are described. Probes are disclosed which are labeled at a cysteine or lysine residue and also probes labeled at both cysteine and lysine with two different fluorophores. These probes are useful for determination of unbound bilirubin levels in a fluid sample.
    Type: Application
    Filed: August 24, 2012
    Publication date: February 12, 2015
    Inventors: Alan Marc Kleinfeld, Andrew Henry Huber, James Patrick Kampf, Thomas Kwan, Baolong Zhu
  • Publication number: 20150031145
    Abstract: Compositions, methods, articles of manufacture, and kits are provided for storage and delivery of proteins.
    Type: Application
    Filed: July 24, 2014
    Publication date: January 29, 2015
    Inventors: Clayton T. McKee, William Strong
  • Publication number: 20150031049
    Abstract: Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich ?-2-glycoprotein (LRG); S100-A8 (calgranulin); ?-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-?-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and ?-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 29, 2015
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Alex Kentsis, Hanno Steen, Richard Bachur
  • Publication number: 20150024206
    Abstract: The present invention relates in a first aspect to a method of coating surfaces of substrates with a lattice-like structure. In particular, the present invention relates to an in vitro method of coating surfaces by binding of epsin or a fragment thereof on the surface and, thereafter, binding of a compound forming the lattice like structure, in particular, binding of the clathrin heavy chain, to the epsin bound on the surface, thus, obtaining a coated substrate having a lattice like structure on the surface. In another aspect, the present invention relates to an in vitro method of producing nanometer-sized liposomes having a clathrin structure on its surface. In addition, substrates, like elements or devices, with coated surfaces having a lattice-like structure on the surface are provided obtainable by a method according to the present invention.
    Type: Application
    Filed: February 6, 2013
    Publication date: January 22, 2015
    Applicant: MEDIZINISCHE HOCHSCHULE HANNOVER
    Inventors: Philip Dannhuser, Ernst Ungewickell